Alvotech Secures $165 Million to Fuel Biosimilar Breakthroughs

2026-06-18 companies

Reykjavik, Thursday, 18 June 2026.
Alvotech has successfully closed a $165 million capital raise through a public offering and private placement, marking one of the largest funding rounds in biosimilar development this year. The proceeds will accelerate the company’s pipeline of nine biosimilar candidates, targeting high-cost biologics like Humira and Stelara. What makes this raise stand out? It signals strong investor confidence in Alvotech’s ability to disrupt the $300 billion global biologics market with affordable alternatives. With five approved biosimilars already on the market, this funding could position Alvotech as a leader in the next wave of cost-saving therapies.

The $165 Million Breakdown: Public Offering and Private Placement

Reykjavik-based Alvotech (NASDAQ: ALVO; ALVO-SDB) has successfully closed a dual financing round, raising a total of $165 million through a combination of public offering and private placement [1]. The public offering, which closed on June 17, 2026, involved the sale of 26,066,667 ordinary shares at $3.75 per share, generating gross proceeds of approximately $97.75 million 2501.25 before underwriting discounts and commissions [1]. Concurrently, the company entered into a private placement agreement with institutional investors in the European Economic Area (EEA), issuing 17,826,666 ordinary shares at the same price point, expected to yield an additional $67 million 2501.25 in gross proceeds [1]. The private placement is slated to close on or about June 25, 2026, subject to customary closing conditions [1]. This financing round represents a significant upsizing from the initially proposed $125 million target announced on June 15, 2026, reflecting strong investor demand [2].

Capital Structure and Market Impact

The $165 million capital infusion will increase Alvotech’s issued share capital to 390,431,480 ordinary shares, a substantial expansion from its pre-offering position [1]. This dilution comes at a time when the company’s market capitalization stands at approximately $1.22 billion, based on its June 18, 2026 closing price [3]. The offering price of $3.75 per share represents a strategic pricing decision, aligning with the company’s previous $152 million equity raise just days earlier, which also priced shares at $3.75 [4]. Notably, Alvotech’s stock has shown volatility following similar capital raises, with an average next-day decline of -8.73% observed in past offerings [2]. As of May 29, 2026, short interest in ALVO stood at 2.55% of shares outstanding, with an average 6.95 days to cover, indicating moderate bearish sentiment in the market [2].

Strategic Allocation of Funds: Pipeline and Balance Sheet Priorities

Alvotech has outlined a comprehensive strategy for deploying the $165 million in net proceeds, with a clear focus on advancing its biosimilar pipeline and strengthening its financial position. The company intends to allocate funds toward the continued development of its biosimilar assets, working capital, and general corporate purposes [1]. Specific areas of investment include intellectual property protection, commercial expenditures, capital expenditures, potential acquisitions or collaborations, pre-clinical and clinical development, research and development, pre-commercialization activities, and the repayment or refinancing of indebtedness [1][4]. This strategic allocation comes as Alvotech faces a substantial debt load, reported at $1.46 billion as of June 18, 2026 [3]. The company’s pipeline includes nine disclosed biosimilar candidates targeting high-value therapeutic areas such as autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [1][5].

Regulatory Milestones and Commercial Partnerships

Alvotech’s funding round arrives at a critical juncture in its regulatory and commercial journey. The company has already achieved significant milestones, with five biosimilars approved and marketed globally: adalimumab (Humira®), ustekinumab (Stelara®), golimumab (Simponi®), aflibercept (Eylea®), and denosumab (Prolia®/Xgeva®) [1][5]. In January 2026, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for AVT05, Alvotech’s golimumab biosimilar, with a parallel filing accepted by the European Medicines Agency [5]. This follows a pattern of strategic regulatory submissions, including the June 2026 acceptance of AVT16, an interchangeable biosimilar to Entyvio®, which could be pharmacy-substituted without prescriber intervention if approved [6]. Alvotech’s commercial strategy is bolstered by partnerships with major pharmaceutical companies, including Teva, Stada, and ADVANZ Pharma, spanning markets in the United States, Europe, Japan, China, and other regions [5].

Underwriters and Regulatory Framework

The public offering was managed by a consortium of leading investment banks, with BofA Securities, Jefferies, and Evercore ISI serving as joint book-running managers [1][2]. The underwriters were granted a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions [1]. This financing round was conducted pursuant to a registration statement on Form F-3, which Alvotech filed with the U.S. Securities and Exchange Commission (SEC) on October 20, 2023, and which was declared effective on October 30, 2023 [1][2]. The Form F-3 provides Alvotech with a streamlined process for future capital raises, reflecting the company’s ongoing need for funding to support its ambitious pipeline and commercialization efforts.

Investor Confidence and Market Disruption Potential

The successful $165 million capital raise underscores strong investor confidence in Alvotech’s ability to disrupt the $300 billion global biologics market with affordable biosimilar alternatives [GPT]. Biosimilars, which are highly similar versions of approved biologic medicines, offer significant cost savings to healthcare systems, with potential price reductions of 15-30% compared to reference biologics [GPT]. Alvotech’s focus on complex biosimilars, including those targeting blockbuster drugs like Humira and Stelara, positions the company at the forefront of this market shift. The company’s founder and former CEO, Robert Wessman, has been a vocal advocate for biosimilars as a means to improve global healthcare access, a vision that continues to guide Alvotech’s strategy [1]. With five approved biosimilars already on the market and nine candidates in development, Alvotech is well-positioned to capitalize on the growing demand for cost-effective biologic therapies, particularly in emerging markets where healthcare affordability remains a critical challenge [5].

Sources

biosimilars biotechnology funding